Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

2.4%

1 terminated out of 41 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

12%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results83% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (5)
Early P 1 (1)
P 1 (12)
P 2 (12)
P 3 (5)

Trial Status

Recruiting18
Active Not Recruiting9
Completed5
Unknown4
Not Yet Recruiting3
Terminated1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT07076212Phase 2Recruiting

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

NCT07157033Phase 1RecruitingPrimary

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

NCT04665947Early Phase 1Recruiting

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

NCT00669734Phase 1Active Not RecruitingPrimary

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

NCT06453486Phase 2RecruitingPrimary

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

NCT04172532Phase 1RecruitingPrimary

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT06998940Phase 3RecruitingPrimary

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT05825066Phase 2Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT04395469Not ApplicableActive Not Recruiting

FAZA PET/MRI Pancreas

NCT06850623Phase 2RecruitingPrimary

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

NCT06673017Phase 1Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06861088Phase 3Recruiting

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06381154Phase 2RecruitingPrimary

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

NCT05679674Not ApplicableRecruiting

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT07319910UnknownPrimary

Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

NCT06861452Phase 1RecruitingPrimary

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

NCT04570943Phase 2RecruitingPrimary

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT05034627Phase 1Active Not RecruitingPrimary

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT07241663RecruitingPrimary

Surgery for Locally Unresectable Pancreatic Cancer

NCT06132087Not ApplicableActive Not RecruitingPrimary

PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy

Scroll to load more

Research Network

Activity Timeline